Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

RAYDIAX TACT RAYDIAX TACT, Next-Generation Imaging for Interventional Oncology

Coordinator
Raydiax GmbH, Germany
Runs
1 June 2026 to 31 May 2028
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101297741

What the project is doing

In the project's own words, from its summary on CORDIS.

Interventional Oncology (IO) is emerging as the fourth pillar of cancer care. These procedures involve guiding millimeter-thin instruments through the skin directly into tumors, demanding submillimeter precision. Instrument placement is monitored using non-invasive imaging, yet – unlike in heart attack and stroke, where dedicated imaging is well established – IO still lacks a tailored solution, facing many challenges such as spatial constraints, high radiation exposure, and poor integration with surgical tools and workflows.

RAYDIAX has addressed this gap by developing the first imaging solution purpose-built for Interventional Oncology: the Therapy Assistance Computed Tomograph TACT. TACT embodies a uniquely integrated system architecture that delivers three core advantages: hybrid imaging, dose optimization, and seamless interventional workflow. Using a TACT generates substantial socio-economic value by enabling resource- and patient-sparing cancer care, expanding access to minimally invasive treatments to over 1 million patients annually.

We primarily target the image-guided surgery systems market, estimated at €6.5 billion in 2025 and expected to grow to €9.2B by 2032, at a CAGR of 6%. Additional growth opportunities arise from the robotic surgery market, giving a large market potential of an additional €18.2B.The TACT solution is at TRL 6 as we have completed and demonstrated its “First Ablation Prototype” with imaging on phantoms, animals, and body donors.

In the EIC Accelerator project, RAYDIAX aims to build two pre-commercial systems to conduct clinical on-site validation studies and obtain CE and FDA approvals in parallel.

Topics

Who is involved

OrganisationCityCountryRole
Raydiax GmbHMagdeburgGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI